Sugi Predict
/ Targets
/ ALG1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to ALG1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| High Dose or High Dose Frequency Study of Alglucosidase Alfa |
PHASE4 | COMPLETED |
| China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD |
PHASE4 | RECRUITING |
| Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of GlcNAc on Tear Production in NGLY1-CDDG |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis |
PHASE1/PHASE2 | RECRUITING |
| An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy |
PHASE2 | COMPLETED |
| Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients |
PHASE2 | ENROLLING_BY_INVITATION |
| 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG |
PHASE2 | COMPLETED |
| Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis |
PHASE2 | COMPLETED |
| A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases |
PHASE1 | COMPLETED |
| A Study of the Tolerance, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers |
PHASE1 | COMPLETED |
| Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) |
nan | WITHDRAWN |
| Biomarker for Mannosidosis Disease (BioMannosidosis) |
nan | WITHDRAWN |
| The Natural History of Alpha-Mannosidosis |
nan | COMPLETED |
| Glycosylation in Patients With Galactosaemia |
nan | COMPLETED |
| Registry Gangliosidoses |
nan | UNKNOWN |
| Efficacy of Intravaginal Carboxymethyl-β-glucan and Polycarbophil on Low-grade Cervical Lesions (GLUCANCIN) |
nan | UNKNOWN |
| Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease |
nan | WITHDRAWN |
| Longitudinal Studies of the Glycoproteinoses |
nan | COMPLETED |
| Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders |
nan | RECRUITING |
| Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation |
nan | COMPLETED |
| Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease |
nan | COMPLETED |
| A Natural History Study of the Gangliosidoses |
nan | RECRUITING |
| The Classification and Cause of Leukodystrophies of Unknown Cause |
nan | COMPLETED |
| Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease |
nan | APPROVED_FOR_MARKETING |
| Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing |
nan | UNKNOWN |
| Characterization of the Patient Population With Galactosialidosis |
nan | COMPLETED |
| Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease |
nan | NO_LONGER_AVAILABLE |
| The Natural History of Sialidosis Type I |
nan | RECRUITING |
| Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a ALG1 binder may also engage these)